A five-year study, called Mammo-50, that followed women aged 50 and older with a breast cancer diagnosis and surgery has been ...

The High-Risk Cancer Surveillance Clinic helps patients detect their cancer risk and develop a care plan from there. Sponsored by Overlake Medical Center and Clinics ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Patients with ulcerative colitis (UC) are at increased risk of colorectal carcinoma. 1, 2 Many clinicians practice colonoscopic surveillance in these patients in the hope of detecting dysplasia or an ...

Feb. 7, 2025 — Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to ... Personalized Cancer ...

Cancer of the tonsil is a rare type of head and neck cancer. Cancer happens when abnormal cells start to divide and grow in an uncontrolled way. Symptoms often include a painless neck lump and a sore ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Most of the rest of this information is about hepatocellular carcinoma and will be referred to as liver cancer. About 10% to 20% of liver cancers start in the cells that line the small bile ducts ...